'DLF may earn Rs 1500 crore via asset monetisation'

Prakash Agarwal, Equity analyst (India Pharma and Property) at RBS says that Ranbaxy is all set to launch Lipitor in US at time. He expects asset monetisation from DLF to the tune of Rs 1500 crore in the next three months.

Related Videos